Post-operative avoidance of radiotherapy: biomarker selection of women categorised to be in a very low risk group by IHC4+C.
Disease site: Breast cancer
Treatment modality: Radiotherapy
Status: Open to recruitment
PRIMETIME is a phase III, multicentre trial which tests whether radiotherapy can be safely avoided in patients considered to have such a low risk of local recurrence that the potential absolute gain from radiotherapy does not outweigh the established risks associated with breast radiotherapy.
PRIMETIME will use immunohistochemical biomarkers with clinical information (IHC4+C) to direct selective avoidance of breast radiotherapy. The IHC4+C algorithm will be used to risk stratify patients into a very low risk group (recommended avoidance of radiotherapy) or not (standard radiotherapy).
Approximately 2,400 patients will be registered over four years to recruit 1,500 patients in the no radiotherapy group. All patients will be followed up for 10 years.
Chief Investigator: Dr Charlotte Coles, The University of Cambridge
ICR-CTSU Scientific Lead: Professor Judith Bliss
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research (ICR)
Funding: Cancer Research UK
Links to PRIMETIME on the UK Clinical Trials Gateway and a plain English summary from Cancer Research UK will be added once available.
Publications and presentations
C.C. Kirwan, C.E. Coles, J. Bliss, On Behalf of the PRIMETIME Protocol Working Group; It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence http://dx.doi.org/10.1016/j.clon.2016.06.007